EMERYVILLE

Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, May 9, 2024
PFS, FDA, SLATE, Administration, Research, HLA, Death, CRC, Doctor of Philosophy, National Cancer Institute, Vaccine, Development, IND, Melinda French Gates, NCI, AACR, Food, ESCMID, Roche, Messenger, HIV, Therapy, CEPI, Neoplasm, Infection, Gritstone bio, DNA, GMP, Clinical trial, Progression-free survival, Human services, Immunotherapy, Spark Therapeutics, MD, Disease, Patient, Acquisition, VAF, PD, COVID-19, Pharmaceutical industry

-- Gritstone to host conference call today at 4:30pm ET --

Key Points: 
  • In April 2024, Gritstone appointed Stephen Webster to its Board of Directors.
  • Mr. Webster was the Chief Financial Officer of Spark Therapeutics from July 2014 until its acquisition by Roche for $4.3 billion in December 2019.
  • Gritstone expects to share mature PFS data and additional long-term ctDNA data in the third quarter of 2024.
  • In April 2024, Gritstone presented a poster highlighting the durability and potential broad utility of its samRNA COVID-19 vaccine at ESCMID Global 2024.

4DMT Reports First Quarter 2024 Financial Results and Operational Highlights

Retrieved on: 
Thursday, May 9, 2024
FDA, Regenerative medicine, Research, Choroideremia, Biopsy, European Medicines Agency, Injection, Overalls, Inflammation, Food, Alpha-1 antitrypsin, Cystic fibrosis, Chelsea Handler, Intravitreal administration, Conference, Retina, Atypical hemolytic uremic syndrome, DME, Angiogenesis, PRISM, AMD, Safety, Security (finance), Cash, Retinitis pigmentosa, Exercise, PRIME, EMA, NHP, Clinical trial, A1AT, ASRS, ARVO, ECFS, Șaeș, Cubic foot, Patient, Society, Geographic atrophy, Pharmaceutical industry

“The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

Key Points: 
  • “The first quarter of 2024 kicks off another transformative year for 4DMT with exceptional progress across our product pipeline and platform in multiple therapeutic areas, particularly our lead program 4D-150 in large market VEGF-driven retinal diseases,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • R&D Expenses: Research and development expenses were $27.9 million for the first quarter of 2024, as compared to $22.4 million for the first quarter of 2023.
  • G&A Expenses: General and administrative expenses were $10.3 million for the first quarter of 2024, as compared to $8.0 million for the first quarter of 2023.
  • Net Loss: Net loss was $32.4 million for the first quarter of 2024, as compared to net loss of $28.7 million for the first quarter of 2023.

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Retrieved on: 
Thursday, May 9, 2024
Cream, CVR, Sale, FDA, BRAF V600, Organon, NDA, Food, Compugen, Department of Defence, Economics, Female, BRAF, PDUFA, Blue Owl Capital, Patient, Bayer, Acquisition, Share repurchase, Food and Drug Administration, Defense, Pharmaceutical industry

EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.

Key Points: 
  • Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib);
    EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2024 financial results and highlighted recent activities.
  • XOMA receives 100 percent of the DSUVIA® economics until a threshold is achieved; thereafter, XOMA retains the 15 percent royalty associated with DSUVIA® commercial sales.
  • The 75 percent royalties from Department of Defense purchases and remaining milestone payments will be shared equally between XOMA and Talphera.
  • Dosed first patient in its Phase 3 trial of RZ358; XOMA earned a $5.0 million milestone associated with the event.

NMI Holdings, Inc. Prices $425 Million Senior Unsecured Notes Offering and Enters Into New $250 Million Unsecured Revolving Credit Facility

Retrieved on: 
Tuesday, May 7, 2024
Goldman Sachs, Sale, Prospectus, Truist Financial, Offering, U.S. Bancorp, Bank of Montreal, BMO Capital Markets, RBC Capital Markets, Security (finance), Form, Citibank, Huntington Bancshares, Bank, Note

EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- NMI Holdings, Inc. (Nasdaq: NMIH) (the “Company”) announced today that it has priced its public offering (the “Offering”) of $425 million aggregate principal amount of senior unsecured notes (the “Notes”).

Key Points: 
  • EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- NMI Holdings, Inc. (Nasdaq: NMIH) (the “Company”) announced today that it has priced its public offering (the “Offering”) of $425 million aggregate principal amount of senior unsecured notes (the “Notes”).
  • The Notes will pay interest semiannually at a rate of 6.0% per year and will mature on August 15, 2029.
  • The Company intends to use net proceeds of the Offering to redeem its existing $400 million of 7.375% senior secured notes due June 2025, with the balance to be used for general corporate purposes.
  • The Offering may be made only by means of a prospectus supplement and accompanying base prospectus filed with the SEC.

Grocery Outlet Holding Corp. Announces First Quarter Fiscal 2024 Financial Results

Retrieved on: 
Tuesday, May 7, 2024
Acquisition, Depreciation, GAAP, Tax, UGO

EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Grocery Outlet Holding Corp. (NASDAQ: GO) ("Grocery Outlet" or the "Company") today announced financial results for the first quarter of fiscal 2024 ended March 30, 2024.

Key Points: 
  • (3) Includes $125 million for the second through fourth quarters of fiscal 2024 from acquisition of UGO.
  • (4) Includes $7 million for the second through fourth quarters of fiscal 2024 from acquisition of UGO.
  • (5) Includes $15 million for the second through fourth quarters of fiscal 2024 related to anticipated capital improvements for UGO locations.
  • A conference call to discuss the first quarter fiscal 2024 financial results is scheduled for today, May 7, 2024 at 4:30 p.m. Eastern Time.

4DMT to Participate in Upcoming Investor Conference

Retrieved on: 
Tuesday, May 7, 2024

EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at an upcoming investor conference in May.

Key Points: 
  • EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in a fireside chat at an upcoming investor conference in May.
  • Members of the management team will also be available for one-on-one meetings.

Bay Wheels Bikeshare Makes San Mateo County Debut

Retrieved on: 
Wednesday, May 1, 2024
BART, Metropolitan Transit Commission, Transport, Carbon footprint, MTC, Growth, National Bike Month, Multimedia, Student, SFMTA, SAN

SAN FRANCISCO, May 1, 2024 /PRNewswire/ -- The Metropolitan Transportation Commission (MTC) and Lyft today kicked off National Bike Month by joining with partners from BART, the San Francisco Municipal Transportation Agency (SFMTA) and Daly City to cut the ribbon on a new Bay Wheels bikeshare station at the Daly City BART station.

Key Points: 
  • "Daly City is proud to be the home of the first Bay Wheels bikeshare station in San Mateo County," said Mayor Juslyn C. Manalo.
  • "I've seen first-hand how MTC has increased its focus on regional connectivity," said MTC Commissioner and San Mateo County Supervisor David Canepa.
  • MTC later this year will launch a pilot program to provide reduced-cost annual Bay Wheels memberships for area college students.
  • Launched in 2017, Bay Wheels is the Bay Area's regional bikeshare program with over 6,000 bicycles — both pedal-powered and pedal-assist electric bikes — at more than 500 stations in San Jose, San Francisco, Oakland, Berkeley, Emeryville and Daly City.

Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

Retrieved on: 
Thursday, May 2, 2024
Vaccine, Gritstone bio

EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.

Key Points: 
  • EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024.
  • The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.
  • While not required, it is recommended you join five minutes prior to the event's start.
  • An archived replay will be accessible at https://ir.gritstonebio.com/investors/events for 30 days following the event.

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Retrieved on: 
Thursday, April 25, 2024
FDA, Glioma, NDA, Food, Economics, New Drug Application, BRAF, Patient, Therapy, LGG, BRAF V600, Pharmaceutical industry

EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’ New Drug Application (NDA) for OJEMDA™ (tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. 

Key Points: 
  • First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation
    EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’ New Drug Application (NDA) for OJEMDA™ (tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
  • “This is an important milestone for XOMA and our royalty portfolio, but more importantly, it is a watershed event for children living with low-grade gliomas with BRAF alterations that have relapsed or progressed,” stated Owen Hughes, Chief Executive Officer of XOMA.
  • In March 2021, XOMA paid $13.5 million upfront to acquire the $54 million in potential milestones and mid-single digit royalties associated with tovorafenib, plus a share of potential event-based economics, in addition to the economics associated with vosaroxin, from Viracta Therapeutics.

RedAwning Embarks on a Strategic Expansion with the Acquisition of Awning.com

Retrieved on: 
Wednesday, April 24, 2024
Acquisition, Marketing, ROI

Awning.com has been recognized for its innovative approach to remote full-service management for vacation rentals.

Key Points: 
  • Awning.com has been recognized for its innovative approach to remote full-service management for vacation rentals.
  • This acquisition merges two complementary solutions and combines their client bases and operational teams, setting a new standard in the vacation rental marketplace.
  • The Awning.com team and client base also gains access to cutting-edge platform solutions to automate and improve the entire guest journey.
  • This transition is designed to uphold and build upon the exceptional service level that has been a hallmark of Awning.com's success.